Panama’s Ministry of Health (MINSA) has approved a clinical guideline for managing doxycycline post-exposure prophylaxis, known as Doxi-PEP. The ministry’s decision is set out in Resolution No. 817 of October 9, 2026, published on October 16 in Official Gazette No. 30636 B. Its fourth provision establishes that it takes effect upon promulgation. The approved document is a guideline for the provision of healthcare, not general authorization for anyone to use the antibiotic on their own.

The first provision incorporates the guideline as Annex I and an integral part of the resolution. The second makes compliance mandatory nationwide for healthcare facilities and professionals in the public and private sectors, within their respective responsibilities. The obligation therefore applies to providers delivering the care covered by the document, not only to facilities directly administered by the ministry. This makes internal assessment, counseling and follow-up procedures relevant to its implementation.

The guideline addresses prevention of certain sexually transmitted infections after exposure. Its section on assessment and follow-up requires an initial, person-centered evaluation, including a medical history and physical examination to identify risk factors and eligibility criteria. It also considers previous sexually transmitted infections and prior use of prevention strategies. This individual assessment rules out interpreting administrative approval as an automatic recommendation applicable to the entire population.

The document includes specific sections on contraindications, interactions and antimicrobial resistance. The adoption of this document does not replace the exercise of clinical judgment or turn this news report into dosing guidance. For healthcare users, the value of a national framework is that consultations can draw on defined criteria rather than informal information about the medication alone. For providers, implementation requires considering the full annex, as well as the resolution approving it.

The third provision assigns dissemination, monitoring and evaluation of compliance to the General Directorate of Public Health, through the work of its specialized section for sexually transmitted infections, HIV and AIDS. Publication establishes the guideline’s adoption and mandatory status, but does not demonstrate immediate availability of the medication at every facility, free treatment or completed training. These operational conditions must be distinguished from the rules being in force when assessing how the service is delivered in practice.

Research assisted by Sentinel, with editorial verification of official sources. Discover Legislat.ai